Ciprofloxacin Dry Powder for Inhalation in Patients with Non-Cystic Fibrosis Bronchiectasis or Chronic Obstructive Pulmonary Disease, and in Healthy Volunteers-Reference-Cited by-同舟云学术

Ciprofloxacin Dry Powder for Inhalation in Patients with Non-Cystic Fibrosis Bronchiectasis or Chronic Obstructive Pulmonary Disease, and in Healthy Volunteers

Published:2017-02 Issue:1 Volume:30 Page:53-63
ISSN:1941-2711
Container-title:Journal of Aerosol Medicine and Pulmonary Drug Delivery
language:en
Short-container-title:Journal of Aerosol Medicine and Pulmonary Drug Delivery

Author:

Stass Heino¹,Nagelschmitz Johannes¹,Kappeler Dominik²,Sommerer Knut²,Kietzig Claudius²,Weimann Boris³

Affiliation:

1. Bayer Pharma AG, Clinical Pharmacology, Wuppertal, Germany.

2. Inamed GmbH, Gauting, Germany.

3. Chrestos Concept GmbH & Co. KG, Ratingen, Germany.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Pharmaceutical Science,Pulmonary and Respiratory Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/jamp.2015.1282

Reference36 articles.

1. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival

2. Trends in Bronchiectasis Among Medicare Beneficiaries in the United States, 2000 to 2007

3. Bronchiectasis

4. Non-cystic fibrosis bronchiectasis

5. CME: Non-cystic fibrosis bronchiectasis

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ciprofloxacin-Loaded Inhalable Formulations against Lower Respiratory Tract Infections: Challenges, Recent Advances, and Future Perspectives;Pharmaceutics;2024-05-11

2. The quest to deliver high-dose rifampicin: can the inhaled approach help?;Expert Opinion on Drug Delivery;2024-01-02

3. An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome;Pulmonary Pharmacology & Therapeutics;2023-04

4. Radiolabeling Method for Lyophilizate for Dry Powder Inhalation Formulations;Pharmaceutics;2022-03-31

5. In vitro-in vivo correlation of cascade impactor data for orally inhaled pharmaceutical aerosols;Advanced Drug Delivery Reviews;2021-10